Myofascial Release and Foot Mobility in Basketball Players: A Randomized Controlled Trial

September 12, 2024 updated by: Nihat Sarıalioğlu, Giresun University

Acute Effects of Myofascial Release on Foot Mobility and Performance in Basketball Players With Hypomobile feet-a Randomized Controlled Trial

The purpose of this study was to investigate the acute effects of myofascial release on foot mobility and sportive performance in basketball players with hypomobile feet. This study was designed as randomized controlled experimental research.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Hypomobility in the foot structure causes functional limitations. These functional limitations affect the sportive performance negatively, especially in basketball where dynamic movements such as jumping and sudden change of direction are very intense. In this context, reducing hypomobility is important in terms of eliminating performance disorders caused by hypomobility. The purpose of this study was to investigate the acute effects of myofascial release on foot mobility and sportive performance in basketball players with hypomobile feet. This study was designed as randomized controlled experimental research. Twenty-four male basketball players (23.46±2.81 years) participated in the study. Athletes were first subjected to foot mobility, balance and vertical jump tests. Then the participants were divided into two groups as myofascial release (MR) and placebo myofascial release (PMR). Myofascial release was applied to the MR group and placebo myofascial release was applied to the PMR group. After the application, foot mobility and performance measurements were performed again and the results were analyzed. It was observed that there was a significant difference in right foot mobility (RFM), left foot mobility (LFM), vertical jump (VJ) and dynamic balance (DB) parameters after the application in MR group (p<0.001), while there was no change in any parameter after the application in PMR group (p>0.05). The results of this study show that a single session of myofascial release applied to the plantar sole temporarily increased foot mobility and improved vertical jump and dynamic balance performance in basketball players with chronic hypomobility.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
24

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Giresun, Turkey, 28200
        • Giresun University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Basketball players who had hypomobility in at least one foot, had not had a serious foot or ankle injury in the last year, and had been actively licensed for the last five years were included in the study.

Exclusion Criteria:

  • Those who did not meet the inclusion criteria were excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Myofascial release (MR) group
The group that received Graston myofascial application
Other: Myofascial release
Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist.
Other Names:
  • Placebo myofascial release
Placebo Comparator: Placebo myofascial release (PMR) group
The group that received placebo Graston myofascial application
Other: Placebo myofascial release
Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist. Since it was a placebo application, no pressure was applied to the tissues by the physiotherapist during the strokes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
hypomobility measurement
Time Frame: 6 hours
Therefore, firstly, the degree of foot mobility of all participants was measured, and height and body weight measurements the balance characteristics and vertical jump levels of the participants who met the inclusion criteria were determined. TParticipants were not informed which group they were in. The MR group received myofascial release and the PMR group received placebo (superficial) myofascial release. All myofascial release applications were performed by an expert physiotherapist. After the application, the degree of foot mobility, balance characteristics and vertical jump levels of the participants were measured again. In order to determine the duration of the acute effects of mobility after myofascial release, the MR group was subjected to a 2-hour standard basketball training after the second measurements. Foot mobility was measured three more times at one-hour intervals in the first hour of the training, at the end of the training and then at rest.
6 hours

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Height and body weight measurements
Time Frame: 4 hours
The height measurements of the participants were measured with wall-mounted holtain stadiometer and body weight and body mass index (BMI) measurements were measured with Tanita MC-580 body analyzer.
4 hours
Evaluation of foot mobility
Time Frame: 4 hours
The modified navicular drop (MND) test was used to assess foot mobility. The MND test is an easy, valid and clinical method used in the evaluation of foot mobility. In the navicular drop test, the navicular process was palpated externally while the subject was sitting on a chair with the foot in neutral position and the height above the ground was measured. The subject was then made to stand up and place one foot on a specially designed 10.16 cm (4 inch) high box without weight. The height above the ground of the navicular process of the loaded foot was measured again. Feet with a difference of less than 4 mm between unweighted and weighted measurements were recorded as hypomobile. The reference values of navicular mobility in the MND test are 0-4 mm hypomobile foot, 5-9 mm neutral foot and 10 mm or more hypermobile foot.
4 hours
Vertical jump measurements
Time Frame: 4 hours
Vertical jump values were performed with arm swing countermovement jump technique using smart speed brand electronic jump mat. The athlete took a position on the jumping mat with feet one shoulder length apart. Then, when he felt ready, he stretched downward and jumped vertically to the highest point he could jump and fell back on the mat. Three attempts were made in the correct position, 3 seconds rest time was allowed between each jump, and the best degree was recorded in cm. The jumps were repeated with the knees flexed while the athlete remained in the air.
4 hours
Determination of balance levels
Time Frame: 4 hours
The balance score was calculated by summing the standard deviation of the front-to-back swing and the standard deviation of the right-to-left swing. The multiaxial proprioceptive assessment module of the isokinetic measurement system was used to determine the dynamic balance levels. First, the device was calibrated and the system was introduced to the volunteers. The volunteers' feet were placed on the platform with reference to the x and y lines on the platform. In the measuring position, the hands were drooping and the feet were bare. Measurements were made in bipedal and 10 difficulty levels for 60 seconds. The test was stopped and restarted when situations such as falling or touching any part of the device occurred during the measurement. Dynamic balance levels were assessed using the average tracking error (ATE).
4 hours
Myofascial release application
Time Frame: 4 hour
Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist.
4 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Giresun University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Nihat SARIALİOĞLU, PhD, Giresun University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 15, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 15, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 17, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 12, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 12, 2024

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 19, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 19, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 12, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GRU-SBF-NS-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Foot Deformities

Clinical Trials on Myofascial release

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings